Dr. Ruby Chen-Tsai, Applied StemCell’s CSO will be Presenting at the Bio International Convention; June 3-6, 2019 in Philadelphia, PA
Applied StemCell’s Chief Scientific Officer, Dr. Ruby Chen-Tsai will be giving a presentation at the Bio International Convention to be held in Philadelphia, PA from June 2-6, 2019. The Bio Convention is hosted by Biotechnology Innovation Organization (BIO) and will be attended by > 1000 privately, publicly and government funded biotechnology companies, academic institutions and organizations from all over the world. The BIO Convention offers a global platform for networking and collaboration between Bio Pharma companies and organizations via its BIO One-on-One Partnering™ program.
Come and hear Dr. Ruby Chen-Tsai talk about Applied StemCell’s proprietary technologies, therapeutic advances, and more at the convention.
Date: Tuesday June 4, 2019
Session: Company Presentations
Presentation Date, Time and Room: Tuesday, June 4 2:00 PM Theater 3
Speaker: Ruby Chen-Tsai, PhD
Presentation Length: 13 Minutes
Applied StemCell Inc. (ASC) is a fast-growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry.
Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines.
We are moving forward to various research and therapeutic projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression and are characterized by high genetic penetrance.
Session ID: 502558